Benzinga | Aug 2, 2021 06:10AM EDT

HC Wainwright & Co. Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $18

HC Wainwright & Co. analyst Ed Arce maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Neutral and lowers the price target from $21 to $18.